ClinicalTrials.Veeva

Menu

Ginkgo Biloba Extract in the Treatment of Schizophrenia

B

Beijing HuiLongGuan Hospital

Status

Completed

Conditions

Schizophrenia

Treatments

Drug: Placebo oral tablet
Drug: Ginkgo Biloba Extract

Study type

Interventional

Funder types

Other

Identifiers

NCT05258123
CASPsy4

Details and patient eligibility

About

We investigated the effects of Ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia

Full description

Objective: This study aimed to evaluate the effect of Ginkgo biloba extract in the treatment of symptoms and cognitive functioning in 200? chronic patients with schizophrenia

Methods:

  1. Clinical Trial: This is a randomized, double-blind and parallel controlled trial in the chronic patients with schizophrenia. The study consists of 12 weeks of double-blind treatment.
  2. Assessment Procedures:

2.1 Primary Outcome Variable: Patients were assessed by two clinical trained staff, who were blind to the treatment protocols, by using the Positive and Negative Syndrome Scale (PANSS) to assess the psychopathology and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to evaluation the cognitive functioning. Patients were interviewed at screening, and at baseline, 4? weeks, 12? weeks.

2.2 Side effects: The side effect rating scale (UKU) was used to assess the side effect at baseline, 4? weeks, and 12? weeks.

2.3 Weight gain measurement: weigh was measured every week.

Enrollment

100 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Diagnosis of schizophrenia by two senior psychiatrists
  • Between 18 and 60 years and Han Chinese
  • Duration of symptoms at least 12 months
  • Current psychotic symptoms of moderate severity

Exclusion criteria

  • A Diagnostic and Statistical Manual of Mental Disorders IV Axis I diagnosis other than schizophrenia
  • Documented disease of physical diseases including, but not limited to stroke, tumor, Parkinson's disease, Huntington's disease, seizure, epilepsy, history of brain trauma;
  • Pregnant or breast-feeding female'
  • Subjects who suffered from alcohol or illegal durg abuse/dependence

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

100 participants in 2 patient groups, including a placebo group

active drug
Active Comparator group
Description:
A fixed titration to 360mg (or nine tables) daily of Ginkgo biloba extract was administered with three times daily dosage throughout the study
Treatment:
Drug: Ginkgo Biloba Extract
placebo
Placebo Comparator group
Description:
A nine tables of placebo were administered with three times daily dosage throughout the study
Treatment:
Drug: Placebo oral tablet

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems